0001209191-23-002486.txt : 20230106
0001209191-23-002486.hdr.sgml : 20230106
20230106203553
ACCESSION NUMBER: 0001209191-23-002486
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230105
FILED AS OF DATE: 20230106
DATE AS OF CHANGE: 20230106
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kumar Neil
CENTRAL INDEX KEY: 0001742485
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38959
FILM NUMBER: 23516315
MAIL ADDRESS:
STREET 1: C/O EIDOS THERAPEUTICS, INC.
STREET 2: 101 MONTGOMERY STREET, SUITE 2550
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BridgeBio Pharma, Inc.
CENTRAL INDEX KEY: 0001743881
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3160 PORTER DR.
CITY: PALO ALTO
STATE: CA
ZIP: 94304
BUSINESS PHONE: (650) 391-9740
MAIL ADDRESS:
STREET 1: 3160 PORTER DR.
CITY: PALO ALTO
STATE: CA
ZIP: 94304
FORMER COMPANY:
FORMER CONFORMED NAME: BridgeBio Pharma LLC
DATE OF NAME CHANGE: 20180618
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-01-05
0
0001743881
BridgeBio Pharma, Inc.
BBIO
0001742485
Kumar Neil
C/O BRIDGEBIO PHARMA, INC.
3160 PORTER DR.
PALO ALTO
CA
94304
1
1
0
0
CEO and President
Common Stock
2023-01-05
4
S
0
120000
7.6738
D
1492722
I
See Footnote
Common Stock
4813197
D
Common Stock
995686
I
See Footnote
This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person as co-trustee of the Kumar Haldea Revocable Trust on December 5, 2022.
Represents the weighted average sale price of the shares sold from $7.38 to $7.90 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
The shares are held by Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
/s/ Brian C. Stephenson, Attorney-in-Fact
2023-01-06